文献速递母胎医学

母亲西罗莫司治疗胎儿广泛淋巴管畸形:六例病例的选择标准、管理与结局

Maternal Sirolimus Therapy for Fetal Extensive Lymphatic Cystic Malformation: Selection Criteria, Management, and Outcomes in a Series of Six Cases.
PubMed 文献 · Prenat Diagn · 2026-08-17

本研究描述15例疑似广泛淋巴管畸形胎儿中筛选6例接受母亲西罗莫司治疗的选择标准、管理及结局。治疗始于24至30周以上,母亲不良反应轻微,存在经胎盘药物转移,平均分娩孕周38.1周,5例新生儿病变部分或显著消退。结论认为该治疗在严格选择的妊娠中可行且耐受良好。

要点

  • 母亲西罗莫司治疗胎儿广泛淋巴管畸形可行且耐受良好
  • 治疗期间观察到经胎盘药物转移,母婴药物浓度比值可变
  • 6例中5例新生儿出现病变部分或显著消退

核心结论

  • 母亲西罗莫司治疗对胎儿广泛淋巴管畸形在严格选择的妊娠中可行且耐受良好,并显示经胎盘转移和令人鼓舞的早期围产结局。

主要发现

  • 治疗开始于孕24周至30周以上,母亲不良反应轻微。
  • 观察到经胎盘药物转移,母婴药物浓度比值可变。
  • 平均分娩孕周为38.1周。
  • 6例新生儿中5例出现病变部分或显著消退,采用半定量0-4影像评分评估。

关键数值与推荐

  • 西罗莫司剂量根据母亲谷浓度每周调整。
  • 病变范围变化采用半定量0-4影像评分评估。

临床怎么用

  • 对于严格选择的广泛胎儿淋巴管畸形妊娠,母亲西罗莫司治疗可作为产前干预选项,需基于母亲谷浓度调整剂量并监测母婴安全。

局限性

  • 样本量小(6例治疗),数据有限,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Maternal sirolimus therapy has emerged as a potential prenatal treatment for extensive fetal lymphatic malformations, particularly when associated with the risk of neonatal airway compromise. Data on prenatal indications, pharmacokinetics, and outcomes remain limited. We aimed to describe patient selection, treatment management, maternal and fetal safety, and early outcomes. METHODS: Between December 2023 and May 2025, 15 fetuses with extensive cystic or mixed vascular anomalies suggestive of lymphatic malformations were referred to a national reference center. Prenatal ultrasound and fetal magnetic resonance imaging were performed. After maternal evaluation and informed consent, sirolimus was administered with weekly dose adjustments based on maternal trough levels. Tolerance, drug concentrations at delivery, obstetric outcomes, and neonatal evolution were assessed. Decrease in lesion extent was assessed using a semi-quantitative 0-4 imaging scale. RESULTS: Six fetuses received therapy after the exclusion of nine cases. Treatment began between 24 and over 30 weeks' gestation. Maternal adverse effects were mild. Transplacental drug transfer was observed with variable maternal-fetal ratios. Mean gestational age at birth was 38.1 weeks. Partial or marked lesion regression occurred in five newborns. CONCLUSIONS: Maternal sirolimus therapy appears feasible and well tolerated for extensive fetal lymphatic malformations, demonstrating transplacental transfer and encouraging early perinatal outcomes in carefully selected pregnancies overall.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Guibaud L, Bordas-Fournel M, Cabet S, et al. Maternal Sirolimus Therapy for Fetal Extensive Lymphatic Cystic Malformation: Selection Criteria, Management, and Outcomes in a Series of Six Cases. Prenat Diagn. 2026. PMID: 42607031. doi:10.1002/pd.70230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。